Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Point-of-Care Diagnostics

Jens Goepfert's Biography



Jens Goepfert, Head, University of Tuebingen

Jens Göpfert is a biologist by training. He did his PhD thesis at the University of Hohenheim in Germany and partly at the University of Calgary in Canada. The work was done on the identification of enzymes and the characterization of a biochemical pathway in plants which is producing bioactive compounds used in treatment of human diseases by molecular and biochemical methods. He spent one year as a Post-Doc at the University of Hohenheim before he joind the Natural and Medical Sciences Institute (NMI) at the University of Tübingen in Reutlingen, Germany. Currently he is working at the NMI as a Senior Scientist in the Biochemistry department. He is mainly involved in the development and validation of new bead-based multiplexed sandwich immunoassays for new biomarkers for the sensitive detection of drug-induced organ injuries for clinical studies within the SAFE-T project. The aim of this project is to address the current lack of sensitive and specific clinical tests to diagnose and monitor drug-induced organ injury.

Jens Goepfert Image

Immunoassays in Multiplex for Personalized Medicine

Thursday, 10 May 2012 at 16:30

Add to Calendar ▼2012-05-10 16:30:002012-05-10 17:30:00Europe/LondonImmunoassays in Multiplex for Personalized Medicine SELECTBIOenquiries@selectbiosciences.com

Miniaturized multiplexed immunoassays allow the analysis of several dozen of parameters in a single experiment. Within the last decade protein array technologies achieved robust analytical performance and enable to screen for a multitude of parameters requiring only minimal amounts of sample material (1-5). General efforts performed during the last decade within the broad field of biomarker assays will be discussed. A critical analysis of technologies, applications and failures will be discussed together with promising approaches in biomarker discovery and validation like the FDA’s critical path initiative and the Europe-based public–private Innovative Medicines Initiative (IMI) (6,7).


Add to Calendar ▼2012-05-10 00:00:002012-05-11 00:00:00Europe/LondonPoint-of-Care DiagnosticsSELECTBIOenquiries@selectbiosciences.com